CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Fórmula:C98H138F3N21O39Pureza:98%Cor e Forma:SolidPeso molecular:2291.25PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Fórmula:C40H42N12O5Peso molecular:770.34011dCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Fórmula:C14H11ClN4OSPureza:98.48% - 99.41%Cor e Forma:SolidPeso molecular:318.78BSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Fórmula:C43H48N10O8Cor e Forma:SolidPeso molecular:832.9HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Fórmula:C28H29Cl2F3N4O4Cor e Forma:SolidPeso molecular:613.46CDK4/6-IN-5
CAS:<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Fórmula:C22H28ClFN6O4SCor e Forma:SolidPeso molecular:527.01CPS2
CAS:<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Fórmula:C38H42N12O10S2Cor e Forma:SolidPeso molecular:890.94CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319CDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Fórmula:C20H21F2N9Cor e Forma:SolidPeso molecular:425.448JHD205
<p>JHD205 is an inhibitor of CDK4/6.</p>Fórmula:C32H40F2N8OCor e Forma:SolidPeso molecular:590.71IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Fórmula:C23H32FN5O2SiCor e Forma:SolidPeso molecular:457.625EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Cor e Forma:Odour SolidCimpuciclib
CAS:<p>Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.</p>Fórmula:C30H35FN8OCor e Forma:SolidPeso molecular:542.663CDK6/9-IN-1
CAS:<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Fórmula:C22H25ClN8OCor e Forma:SolidPeso molecular:452.95CDK4/6-IN-11
CAS:<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Fórmula:C43H49N11O7Cor e Forma:SolidPeso molecular:831.92PROTAC CDK9 degrader-7
CAS:<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Fórmula:C43H50Cl2N8O9Cor e Forma:SoildPeso molecular:893.81CDK-TCIP2
<p>DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.</p>Fórmula:C52H67ClN12O8S2Cor e Forma:SolidPeso molecular:1087.75NecroIr2
<p>NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.</p>Fórmula:C46H30ClIrN6O2Cor e Forma:SolidPeso molecular:926.44WAY-322243
CAS:<p>WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.</p>Fórmula:C18H18N2O2SPureza:99.88%Cor e Forma:SoildPeso molecular:326.41
